Lawsuit for Investors in Shares of Alexion Pharmaceuticals, Inc. (ALXN) Announced by Shareholders Foundation

SAN DIEGO, CA / ACCESSWIRE / January 9, 2017 / The Shareholders Foundation, Inc. announces that a lawsuit was filed for certain purchasers of NASDAQ: ALXN shares against Alexion Pharmaceuticals, Inc. over alleged Securities Laws Violations.

Investors who purchased shares of Alexion Pharmaceuticals, Inc. ALXN have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

On June 6, 2016, Alexion Pharmaceuticals, Inc. announced topline results from Phase 3 REGAIN Study of Eculizumab (Soliris) in patients with refractory generalized myasthenia gravis.

On November 9, 2016, Alexion Pharmaceuticals, Inc. announced that the Audit and Finance Committee of the Board of Directors is conducting an investigation into allegations that recently have been made by a former employee with respect to the Company's sales practices of Soliris. Alexion Pharmaceuticals, Inc. said that the Audit and Finance Committee is investigating whether Company personnel have engaged in sales practices that were inconsistent with Company policies and procedures and the related disclosure and other considerations raised by such practices and that the Audit and Finance Committee has retained outside counsel to assist it in the investigation.

The plaintiff alleges that the defendants issued materially false and misleading statements to investors and/or failed to disclose that Alexion Pharmaceuticals, Inc. employed improper sales practices with respect to Soliris, that consequently, Alexion's revenues from Soliris sales were unlikely to be sustainable, and that as a result, Alexion's public statements were materially false and misleading at all relevant times.

Those who purchased Alexion Pharmaceuticals, Inc. ALXN shares should contact the Shareholders Foundation, Inc.

The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

CONTACT:

Shareholders Foundation, Inc.
Michael Daniels
+1 (858) 779-1554
mail@shareholdersfoundation.com
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108

SOURCE: Shareholders Foundation, Inc.